Abstract
A survey of existing methods of pathogenetic and symptomatic treatment of primary biliary cirrhosis has been made and it has reviewed prospective directions of its therapy. Is also presents a retrospective analysis of our own data of S-adenosylmethionine (Heptral) in 27 patients PBC receiving UDCA basic therapy. In its application intravenously of 400 mg 2 times daily for 3 weeks showed a reduction in the severity of pruritus, assessed by visual analogue scale, a subjective decrease fatigability and a decrease level of serum bilirubin.
MeSH terms
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal / therapeutic use
-
Fatigue / drug therapy
-
Fatigue / etiology
-
Glucocorticoids / administration & dosage
-
Glucocorticoids / therapeutic use
-
Humans
-
Immunosuppressive Agents / administration & dosage
-
Immunosuppressive Agents / therapeutic use
-
Liver Cirrhosis, Biliary / complications
-
Liver Cirrhosis, Biliary / drug therapy*
-
Practice Guidelines as Topic
-
Pruritus / drug therapy
-
Pruritus / etiology
-
Receptors, Cytoplasmic and Nuclear / agonists
-
S-Adenosylmethionine / administration & dosage
-
S-Adenosylmethionine / therapeutic use
-
Treatment Outcome
-
Ursodeoxycholic Acid / administration & dosage
-
Ursodeoxycholic Acid / therapeutic use
Substances
-
Antibodies, Monoclonal
-
Glucocorticoids
-
Immunosuppressive Agents
-
Receptors, Cytoplasmic and Nuclear
-
Ursodeoxycholic Acid
-
S-Adenosylmethionine